Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

HJHyejeong JangAKAndrew KinLALois Ayash

Discussion

Loading...

Member takes

Overview

Evaluation reveals post-transplant cyclophosphamide doesn't significantly alter outcomes for myelofibrosis patients in stem cell transplantation, indicating the need for further studies.

Key Points

  • To evaluate the outcomes of post-transplant cyclophosphamide in patients with myelofibrosis undergoing hematopoietic stem cell transplantation.
  • Included adult patients with primary or secondary myelofibrosis undergoing transplantation from 2005 to 2024.
  • Assessed the impact of donor type, conditioning regimen, and GVHD prophylaxis on transplant outcomes.
  • Analyzed acute and chronic graft-versus-host disease and survival rates.
  • 69 patients were identified; 33.3% had secondary myelofibrosis.
  • Post-transplant cyclophosphamide did not show significant differences in outcomes compared to calcineurin inhibitor regimen.
  • Higher risks of mortality and relapse were associated with mismatched donors.

Cite This Study

Jang et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd03https://doi.org/10.1182/blood-2025-7832
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis2025
  2. 2MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis2025
  3. 3Mismatched unrelated and haploidentical transplant with post-transplant cyclophosphamide-based graft versus host disease prophylaxis are effective for myelofibrosis2025
  4. 4Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.2025
  5. 5Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation2024 · 3 citations